1. 2363 Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIb trial. (September 2015) Authors: Ettrich, T.; Perkofer, L.; Berger, A.W.; Güthle, M.; Behl, S.; Zipprich, A.; Wörns, M.A.; Waldschmidt, D.T.; Belle, S.; Michl, P.; Seufferlein, T.; Dollinger, M.M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S457 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. TRAINING PROGRAMS PROMOTING DAILY ACTIVITY AND PHYSICAL FUNCTION OF OLDER PATIENTS WITH CANCER: A QUESTIONNAIRE-BASED SURVEY REGARDING INDIVIDUAL NEEDS AND PREFERENCES. (November 2019) Authors: Witte, S.; Medenwald, D.; Golla, A.; Shehu, E.; Vordermark, D.; Michl, P.; Binder, M.; Ruessel, J.; Steckelberg, A.; Schmidt, H. Journal: Journal of geriatric oncology Issue: Volume 10(2019)Supplement 1 Page Start: S73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Visceral Debranching Followed by Neoadjuvant Chemotherapy and Pancreatic Resection for Locally Advanced Pancreatic Cancer: A Phase II Clinical Trial. (2022) Authors: Rebelo, A.; Ukkat, J.; Ronellenfitsch, U.; Michalski, C.W.; Michl, P.; Krug, S.; Kleeff, J. Journal: HPB Issue: Volume 24(2022)Supplement 1 Page Start: S429 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗